keyword
MENU ▼
Read by QxMD icon Read
search

Inhaled corticosteroids pneumonia

keyword
https://www.readbyqxmd.com/read/27877031/the-association-between-inhaled-corticosteroid-and-pneumonia-in-copd-patients-the-improvement-of-patients-life-quality-with-copd-in-taiwan-impact-study
#1
Cheng-Yi Wang, Chih-Cheng Lai, Wei-Chih Yang, Chia-Chieh Lin, Likwang Chen, Hao-Chien Wang, Chong-Jen Yu
To investigate the association between inhaled corticosteroid (ICS) exposure patterns and the risk of pneumonia in chronic obstructive pulmonary disease (COPD) patients, we performed a nested case-control study. Between 1998 and 2010, 51,739 patients, including 19,838 cases of pneumonia, were matched to 74,849 control subjects selected from a cohort of COPD patients using ICSs via risk-set sampling of the database constructed by the National Health Research Institutes of Taiwan. After adjusting for covariates, the current use of ICSs was associated with a 25% increase in the risk of pneumonia (odds ratio [OR] =1...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27864038/a-systematic-review-with-meta-analysis-of-fluticasone-furoate-vilanterol-combination-for-the-treatment-of-stable-copd
#2
Gustavo J Rodrigo, Hugo Neffen
BACKGROUND: Current guidelines recommend the use of inhaled corticosteroids/long-acting beta2-agonists as first-line therapy for COPD patients at risk for acute exacerbations and/or severe airflow limitation. This systematic review assesses available evidence on the efficacy and safety of fluticasone furoate/vilanterol (FF/VI) combination versus each alone, for the treatment of patients with severe to very severe stable COPD. METHODS: Randomized, placebo-controlled trials of >8 weeks of duration were included...
November 15, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27808096/first-maintenance-therapy-for-copd-in-the-uk-between-2009-and-2012-a-retrospective-database-analysis
#3
David Price, Marc Miravitlles, Ian Pavord, Mike Thomas, Jadwiga Wedzicha, John Haughney, Katsiaryna Bichel, Daniel West
Clinical guidelines recommend long-acting bronchodilators as first maintenance therapy for chronic obstructive pulmonary disease (COPD), with inhaled corticosteroids (ICS) reserved for patients with more severe disease and exacerbations. The aim of this analysis was to examine real-life prescribing of first maintenance therapy for COPD in the UK. Data were extracted from the UK Optimum Patient Care Research Database for patients with a first prescription for COPD maintenance therapy between 2009 and 2012 and a diagnosis of COPD at or before the date of the first prescription for COPD maintenance therapy...
November 3, 2016: NPJ Primary Care Respiratory Medicine
https://www.readbyqxmd.com/read/27724847/post-inhaled-corticosteroid-pulmonary-tuberculosis-and-pneumonia-increases-lung-cancer-in-patients-with-copd
#4
Ming-Fang Wu, Zhi-Hong Jian, Jing-Yang Huang, Cheng-Feng Jan, Oswald Ndi Nfor, Kai-Ming Jhang, Wen-Yuan Ku, Chien-Chang Ho, Chia-Chi Lung, Hui-Hsien Pan, Min-Chen Wu, Yung-Po Liaw
BACKGROUND: Inhaled corticosteroids (ICS) have been associated with decreased lung cancer risk. However, they have been associated with pulmonary infections (tuberculosis [TB] and pneumonia) in patients with chronic obstructive pulmonary disease (COPD). TB and pneumonia have increased lung cancer risk. The association between post-ICS pulmonary infections and lung cancer remains unclear. METHODS: We conducted a retrospective cohort study from 2003 to 2010 using the Taiwan National Health Insurance Research Database...
October 10, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27703344/effectiveness-using-higher-inhaled-corticosteroid-dosage-in-patients-with-copd-by-different-blood-eosinophilic-counts
#5
Shih-Lung Cheng, Ching-Hsiung Lin
BACKGROUND: Blood eosinophil counts have been documented as a good biomarker for patients with chronic obstructive pulmonary disease (COPD) using inhaled corticosteroid (ICS) therapy. However, the effectiveness and safety of prescribing high or medium dose of ICS for patients with different eosinophil counts are unknown. METHODS: A post hoc analysis of a previous prospective randomized study was performed for COPD patients using higher dose (HD: Fluticasone 1,000 μg/day) or medium dose (MD: Fluticasone 500 μg/day) of ICS combined with Salmeterol (100 μg/day)...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27616196/efficacy-and-safety-of-lebrikizumab-in-patients-with-uncontrolled-asthma-lavolta-i-and-lavolta-ii-replicate-phase-3-randomised-double-blind-placebo-controlled-trials
#6
Nicola A Hanania, Phillip Korenblat, Kenneth R Chapman, Eric D Bateman, Petr Kopecky, Pierluigi Paggiaro, Akihito Yokoyama, Julie Olsson, Sarah Gray, Cecile T J Holweg, Mark Eisner, Charles Asare, Saloumeh K Fischer, Kun Peng, Wendy S Putnam, John G Matthews
BACKGROUND: In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody, reduced exacerbation rates and improved FEV1 in patients with uncontrolled asthma, particularly in those with high concentrations of type 2 biomarkers (eg, periostin or blood eosinophils). We undertook replicate phase 3 studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma despite inhaled corticosteroids and at least one second controller medication. METHODS: Adult patients with uncontrolled asthma, pre-bronchodilator FEV1 40-80% predicted, and stable background therapy were randomly assigned (1:1:1) with an interactive voice-web-based response system to receive lebrikizumab 37·5 mg or 125 mg, or placebo subcutaneously, once every 4 weeks...
October 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27554300/long-acting-bronchodilator-initiation-in-copd-and-the-risk-of-adverse-cardio-pulmonary-events-a-population-based-comparative-safety-study
#7
Samy Suissa, Sophie Dellaniello, Pierre Ernst
BACKGROUND: Long-acting bronchodilators, including long-acting beta2-agonists (LABA) and the anticholinergic tiotropium, are recommended as initial maintenance therapy in COPD. Studies to date have been limited in size and reported ambivalent results on the comparative risk of cardiovascular, cerebrovascular and pulmonary adverse events between these two long-acting bronchodilators. Moreover, little information is available for the period when treatment is first initiated, a time when subjects may be especially at risk...
August 20, 2016: Chest
https://www.readbyqxmd.com/read/27512933/-chronic-obstructive-pulmonary-disease-copd-rational-diagnostics-and-therapy
#8
R Burkhardt, W Pankow
In general chronic obstructive pulmonary disease (COPD) can be diagnosed in family practice from history and spirometry. Inconclusive spirometry findings have to be assessed further by techniques available in a pulmonologist's office. Further testing is done for differential diagnostic reasons and for prognostic appraisal. Successful smoking cessation importantly alters the natural downhill course of the disease. Patient education and rehabilitative interventions (e. g. participation in lung sport groups) help to improve life quality...
August 2016: Pneumologie
https://www.readbyqxmd.com/read/27494903/identification-of-novel-macrolides-with-antibacterial-anti-inflammatory-and-type-i-and-iii-ifn-augmenting-activity-in-airway-epithelium
#9
James D Porter, Jennifer Watson, Lee R Roberts, Simren K Gill, Helen Groves, Jaideep Dhariwal, Mark H Almond, Ernie Wong, Ross P Walton, Lyn H Jones, John Tregoning, Iain Kilty, Sebastian L Johnston, Michael R Edwards
BACKGROUND: Exacerbations of asthma and COPD are triggered by rhinoviruses. Uncontrolled inflammatory pathways, pathogenic bacterial burden and impaired antiviral immunity are thought to be important factors in disease severity and duration. Macrolides including azithromycin are often used to treat the above diseases, but exhibit variable levels of efficacy. Inhaled corticosteroids are also readily used in treatment, but may lack specificity. Ideally, new treatment alternatives should suppress unwanted inflammation, but spare beneficial antiviral immunity...
October 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27460163/blood-eosinophil-count-and-pneumonia-risk-in-patients-with-chronic-obstructive-pulmonary-disease-a-patient-level-meta-analysis
#10
Ian D Pavord, Sally Lettis, Antonio Anzueto, Neil Barnes
BACKGROUND: Inhaled corticosteroids are important in the management of chronic obstructive pulmonary disease (COPD), but can slightly increase the risk of pneumonia in patients with moderate-to-severe COPD. Patients with circulating eosinophil counts of 2% or more of blood leucocytes respond better to inhaled corticosteroids than do those with counts of less than 2% and it was therefore postulated that blood eosinophil count might also have an effect on the risk of pneumonia in patients with COPD...
September 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27453814/allergic-bronchopulmonary-aspergillosis-masquerading-as-recurrent-bacterial-pneumonia
#11
Vu Le Thuong, Lam Nguyen Ho, Ngoc Tran Van
Allergic Bronchopulmonary Aspergillosis (ABPA) can be diagnosed in an asthmatic with suitable radiologic and immunological features. However ABPA is likely to be misdiagnosed with bacterial pneumonia. Here we report a case of ABPA masquerading as recurrent bacterial pneumonia. Treatment with high-dose inhaled corticosteroids was effective. To our best knowledge, this is the first reported case of ABPA in Vietnam.
June 2016: Medical Mycology Case Reports
https://www.readbyqxmd.com/read/27448321/post-inhaled-corticosteroid-pulmonary-tuberculosis-increases-lung-cancer-in-patients-with-asthma
#12
Zhi-Hong Jian, Jing-Yang Huang, Frank Cheau-Feng Lin, Oswald Ndi Nfor, Kai-Ming Jhang, Wen-Yuan Ku, Chien-Chang Ho, Chia-Chi Lung, Hui-Hsien Pan, Min-Chen Wu, Ming-Fang Wu, Yung-Po Liaw
PURPOSE: To evaluate the association between post-inhaled corticosteroid (ICS) pulmonary tuberculosis (TB), pneumonia and lung cancer in patients with asthma. METHODS: The study samples were collected from the National Health Insurance Database. Asthmatic patients who were first-time users of ICS between 2003 and 2005 were identified as cases. For each case, 4 control individuals were randomly matched for sex, age and date of ICS use. Cases and matched controls were followed up until the end of 2010...
2016: PloS One
https://www.readbyqxmd.com/read/27401847/predicting-2-year-risk-of-developing-pneumonia-in-older-adults-without-dementia
#13
Michael L Jackson, Rod Walker, Sei Lee, Eric Larson, Sascha Dublin
OBJECTIVES: To develop three prognostic indices of varying degree of required detail for 2-year pneumonia risk in older adults. DESIGN: Retrospective cohort study. SETTING: Group Health (GH), an integrated healthcare delivery system. PARTICIPANTS: Community-dwelling dementia-free individuals aged 65 and older who had been GH members for at least 2 years before start of follow-up and were enrolled in the Adult Changes in Thought study (N = 3,375; development cohort, n = 2,250; validation cohort, n = 1,125...
July 2016: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/27382276/effect-of-outpatient-therapy-with-inhaled-corticosteroids-on-decreasing-in-hospital-mortality-from-pneumonia-in-patients-with-copd
#14
Yasuhiro Yamauchi, Hideo Yasunaga, Wakae Hasegawa, Yukiyo Sakamoto, Hideyuki Takeshima, Taisuke Jo, Hiroki Matsui, Kiyohide Fushimi, Takahide Nagase
BACKGROUND AND OBJECTIVES: Inhaled corticosteroids (ICS) and long-acting inhaled bronchodilators (IBD) are beneficial for the management of COPD. Although ICS has been reported to increase the risk of pneumonia in patients with COPD, it remains controversial whether it influences mortality. Using a Japanese national database, we examined the association between preadmission ICS therapy and in-hospital mortality from pneumonia in patients with COPD. METHODS: We retrospectively collected data from 1,165 hospitals in Japan on patients with COPD who received outpatient inhalation therapy and were admitted with pneumonia...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27271056/combination-inhaled-steroid-and-long-acting-beta%C3%A2-agonist-in-addition-to-tiotropium-versus-tiotropium-or-combination-alone-for-chronic-obstructive-pulmonary-disease
#15
REVIEW
Maria Ximena Rojas-Reyes, Olga M García Morales, Rodolfo J Dennis, Charlotta Karner
BACKGROUND: The long-acting bronchodilator tiotropium and single-inhaler combination therapy of inhaled corticosteroids and long-acting beta2-agonists (ICS/LABA) are commonly used for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Combining these treatments, which have different mechanisms of action, may be more effective than administering the individual components. OBJECTIVES: To assess relative effects of the following treatments on markers of exacerbations, symptoms, quality of life and lung function in patients with COPD...
June 6, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27257014/dtb-select-6-june-2016
#16
(no author information available yet)
EMA reviews risk of pneumonia with inhaled corticosteroids for COPD ● Updated USA guidance on opioids for chronic pain ● Tackling high-risk prescribing ● Influencing antibiotic prescribing in primary care ● Commuting, BMI and obesity ● Cardiovascular effects of antidepressants ● PPI use and dementia ● Older people and risk of drug interactions.
June 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27215595/the-pharmacological-treatment-of-chronic-obstructive-pulmonary-disease
#17
Adrian Gillissen, Peter Haidl, Martin Khlhäufl, Klaus Kroegel, Thomas Voshaar, Christian Gessner
BACKGROUND: Inhaled corticosteroids (ICS) are markedly less effective against chronic obstructive pulmonary disease (COPD) than against asthma, and also have worse side effects. Whether ICS should be used to treat COPD is currently a matter of debate. METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed and the Excerpta Medica Database (EMBASE) carried out in May 2015. We analyzed clinical trials of ICS for the treatment of COPD with a duration of at least one year, along with meta-analyses and COPD guidelines...
May 6, 2016: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/27203508/fluticasone-furoate-and-vilanterol-and-survival-in-chronic-obstructive-pulmonary-disease-with-heightened-cardiovascular-risk-summit-a-double-blind-randomised-controlled-trial
#18
RANDOMIZED CONTROLLED TRIAL
Jørgen Vestbo, Julie A Anderson, Robert D Brook, Peter M A Calverley, Bartolome R Celli, Courtney Crim, Fernando Martinez, Julie Yates, David E Newby
BACKGROUND: Chronic obstructive pulmonary disease (COPD) often coexists with cardiovascular disease. Treatments for airflow limitation might improve survival and both respiratory and cardiovascular outcomes. The aim of this study was to assess whether inhaled treatment with a combined treatment of the corticosteroid, fluticasone furoate, and the long-acting β agonist, vilanterol could improve survival compared with placebo in patients with moderate COPD and heightened cardiovascular risk...
April 30, 2016: Lancet
https://www.readbyqxmd.com/read/27153510/the-place-of-inhaled-corticosteroids-in-the-treatment-of-chronic-obstructive-pulmonary-disease-a-narrative-review
#19
Pavlina A Andreeva-Gateva, Eleonora Stamenova, Tzvetelin Gatev
Inhaled corticosteroids (ICSs) belong to the armament for treatment of chronic obstructive pulmonary disease (COPD) and as such, they are widely used in real life. This is a narrative review on evidence-based papers published in the English language listed in Medline between 1990 and March 2016 discussing ICS application in COPD. Recent meta-analyses clearly show that ICSs are able to decrease the rate of exacerbation and to delay the decline of lung function, although they do not prolong life, nor stop the progression of the disease...
June 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/27148815/long-acting-muscarinic-antagonist-versus-inhaled-corticosteroid-when-added-to-long-acting-%C3%AE-agonist-for-copd-a-meta-analysis
#20
Yuji Oba, Arul V Chandran, Joe V Devasahayam
The purpose of this study was to systematically review the efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid (ICS) combinations in patients with advanced chronic obstructive pulmonary disease (COPD). Randomized clinical trials of at least 12 weeks of duration comparing LABA/LAMA and LABA/ICS combinations were included. We chose forced expiratory volume in 1 second (FEV(1)), St. George's Respiratory Questionnaire (SGRQ) score, Transitional Dyspnea Index (TDI), COPD Assessment Test (CAT) score, COPD exacerbations, mortality, and other safety parameters as outcome assessment criteria...
December 2016: COPD
keyword
keyword
90082
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"